Protalix BioTherapeutics (PLX) Receivables (2016 - 2025)
Historic Receivables for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $14.4 million.
- Protalix BioTherapeutics' Receivables rose 55717.54% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year increase of 55717.54%. This contributed to the annual value of $2.9 million for FY2024, which is 4482.17% down from last year.
- Per Protalix BioTherapeutics' latest filing, its Receivables stood at $14.4 million for Q3 2025, which was up 55717.54% from $9.4 million recorded in Q2 2025.
- Protalix BioTherapeutics' Receivables' 5-year high stood at $14.4 million during Q3 2025, with a 5-year trough of $1.3 million in Q1 2023.
- Its 5-year average for Receivables is $5.5 million, with a median of $4.6 million in 2021.
- In the last 5 years, Protalix BioTherapeutics' Receivables plummeted by 7792.82% in 2023 and then surged by 55717.54% in 2025.
- Quarter analysis of 5 years shows Protalix BioTherapeutics' Receivables stood at $3.4 million in 2021, then skyrocketed by 33.24% to $4.6 million in 2022, then grew by 14.96% to $5.3 million in 2023, then tumbled by 44.82% to $2.9 million in 2024, then surged by 395.87% to $14.4 million in 2025.
- Its Receivables stands at $14.4 million for Q3 2025, versus $9.4 million for Q2 2025 and $4.7 million for Q1 2025.